Brief: Biomarin Pharmaceutical Q4 EPS USD 0.64
19/02/2025 21:05
Feb 19 (Reuters) - Biomarin Pharmaceutical Q4 revenue USD 747 million vs. IBES estimate USD 713.4 million. * Q4 net income USD 125 million vs. IBES estimate USD 103.9 million * Q4 adjusted EPS USD 0.92 vs. IBES estimate USD 0.53 * Q4 basic EPS USD 0.66
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife